Literature DB >> 11083710

Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.

A L Rafanan1, J Maurer, A C Mehta, R Schilz.   

Abstract

Portopulmonary hypertension (PPHTN) is an uncommon complication of advanced liver disease. Epoprostenol has been effective in the treatment of PPHTN and has been used as a bridge to orthotopic liver transplantation (OLT). The role of OLT in the reversal of PPHTN is unclear. We report a case of severe PPHTN (mean pulmonary artery pressure of 45 mm Hg) that progressed after OLT. Acute dosing with epoprostenol improved the pulmonary vascular resistance by 55% and the cardiac index by 134%. Hemodynamic and symptomatic improvements were maintained after 18 months of long-term treatment with epoprostenol. This is the first reported case of a successful favorable outcome after treatment for progressive PPHTN after OLT. Our case report complements previous reports by highlighting the potential effective use of epoprostenol as a definitive treatment for PPHTN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083710     DOI: 10.1378/chest.118.5.1497

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment.

Authors:  Engin Altintas; Necdet Akkus; Ramazan Gen; M-Rami Helvaci; Orhan Sezgin; Dilek Oguz
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

2.  Portopulmonary hypertension.

Authors:  Ravi P Nayak; Dechun Li; George M Matuschak
Journal:  Curr Gastroenterol Rep       Date:  2009-02

3.  Intraoperative pulmonary hypertension occurred in an asymptomatic patient with pre-existent liver cirrhotic and portal hypertension.

Authors:  Ling Lu; Feng Zhang; Xiang-Cheng Li; Guo-Qiang Li; Chuan-Yong Zhang; Xue-Hao Wang
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

Review 4.  Pulmonary hypertension's variegated landscape: a snapshot.

Authors:  Thomas J Kulik; Eric D Austin
Journal:  Pulm Circ       Date:  2017-03-13       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.